Defective NKT Cell Activation by CD1d+ TRAMP Prostate Tumor Cells Is Corrected by Interleukin-12 with alpha-Galactosylceramide

Circulating Myeloid Dendritic Cells of Advanced Cancer Patients Result in Reduced Activation and a Biased Cytokine Profile in Invariant NKT Cells

(2014) H. J. J. van der Vliet et al.   JOURNAL OF IMMUNOLOGY

Cutting Edge: Programmed Death-1/Programmed Death Ligand 1 Interaction Regulates the Induction and Maintenance of Invariant NKT Cell Anergy

(2014) W.-S. Chang et al.   JOURNAL OF IMMUNOLOGY

iNKT Cells Control Mouse Spontaneous Carcinoma Independently of Tumor-Specific Cytotoxic T Cells

(2010) Matteo Bellone et al.   PLoS One

New Perspectives for Melanoma Immunotherapy: Role of IL-12

(2009) Claudia Cocco et al.   CURRENT MOLECULAR MEDICINE

PD-1/PD-L Blockade Prevents Anergy Induction and Enhances the Anti-Tumor Activities of Glycolipid-Activated Invariant NKT Cells

(2009) V. V. Parekh et al.   JOURNAL OF IMMUNOLOGY

Clinical applications of natural killer T cell–based immunotherapy for cancer

(2008) Shinichiro Motohashi et al.   CANCER SCIENCE

CD1d-restricted iNKT cells, the ‘Swiss-Army knife’ of the immune system

(2008) Jennifer L Matsuda et al.   CURRENT OPINION IN IMMUNOLOGY

Natural killer T cell dysfunction in CD39-null mice protects against concanavalin A-induced hepatitis

(2008) Guido Beldi et al.   HEPATOLOGY

SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade

(2008) M. Fasso et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA